EDITAS MEDICINE, INC. Cash and Cash Equivalents, Period Increase (Decrease)
EDITAS MEDICINE, INC. (EDIT) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$98.78 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-11-08
- EDITAS MEDICINE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$57.55M.
- EDITAS MEDICINE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$207.46M.
- EDITAS MEDICINE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $166.23M, a 93.24% increase year-over-year.
- EDITAS MEDICINE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was -$14.55M.
- EDITAS MEDICINE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $42.14M, a 68.21% decline from fiscal 2015.
- EDITAS MEDICINE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $132.56M, a 1439.39% increase from fiscal 2014.
- EDITAS MEDICINE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $8.61M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-09-30 | -$57.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$265.01M derived: sum of 2 quarters · filed 2017-11-08 | -$98.78M 10-Q · filed 2017-11-08 | -$113.33M derived: sum of 4 quarters · filed 2017-11-08 |
| 2017-06-30 | -$207.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$41.23M 10-Q · filed 2017-08-09 | -$55.78M derived: sum of 3 quarters · filed 2017-08-09 | -$73.55M derived: sum of 4 quarters · filed 2017-11-08 |
| 2017-03-31 | $166.23M 10-Q · filed 2017-05-15 | $151.68M derived: sum of 2 quarters · filed 2017-05-15 | $133.90M derived: sum of 3 quarters · filed 2017-11-08 | $122.35M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-12-31 | -$14.55M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$32.33M derived: sum of 2 quarters · filed 2017-11-08 | -$43.88M derived: sum of 3 quarters · filed 2017-11-08 | $42.14M 10-K · filed 2017-03-03 |
| 2016-09-30 | -$17.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$29.33M derived: sum of 2 quarters · filed 2017-11-08 | $56.69M 10-Q · filed 2017-11-08 | $44.57M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | -$11.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $74.47M 10-Q · filed 2017-08-09 | $62.35M derived: sum of 3 quarters · filed 2017-08-09 | $170.61M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $86.02M 10-Q · filed 2017-05-15 | $73.90M derived: sum of 2 quarters · filed 2017-05-15 | $182.16M derived: sum of 3 quarters · filed 2017-05-15 | $224.04M derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | -$12.12M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | $96.14M derived: sum of 2 quarters · filed 2017-03-03 | $138.01M derived: sum of 3 quarters · filed 2017-03-03 | $132.56M 10-K · filed 2017-03-03 |
| 2015-09-30 | $108.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $150.13M derived: sum of 2 quarters · filed 2016-11-09 | $144.68M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $41.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $36.42M 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | -$5.46M 10-Q · filed 2016-05-13 | |||
| 2014-12-31 | $8.61M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |